Catriona Yale - Jun 28, 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Development Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Jun 28, 2024
Transactions value $
$21,217
Form type
4
Date filed
7/2/2024, 06:56 PM
Previous filing
Jun 13, 2024
Next filing
Aug 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Award $21.2K +1.06K +1.42% $19.94 75.9K Jun 28, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Yale is voluntarily reporting the acquisition of these shares on June 28, 2024 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2 In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on June 28, 2024.